The mission of the Curative Therapies for HIV Scientific Working Group (SWG) is to encourage the development of a cure for HIV, by fostering new ideas and promoting new technology. During the previous funding cycle this continuing SWG was highly successful in its efforts to bring together local researchers and community members with the aim of advancing cure research. As the HIV pandemic continues to affect many millions of lives globally, there is still an urgent need for an HIV cure, so we will continue to support research into curative therapies through our SWG. The long-term objective of our SWG is to stimulate novel research, which can progress into a cure for HIV that can ultimately be transitioned into the clinic, and reduce the global burden of HIV that remains. To achieve our mission the SWG will continue to bring together UW/Fred Hutch CFAR affiliated researchers, unaffiliated external HIV researchers, and community members, through a series of scientific networking events, forums and an annual conference, each with a defined purpose. The goals of this SWG will be attained through two specific aims that are intended to: 1) Provide infrastructure that fosters the exchange of new actionable ideas, engages the community, and promotes the development of novel curative treatments for HIV, and 2) Develop new intra-/inter-CFAR projects and funding applications on curative therapies for HIV. Cooperation between researchers and community members from local, national and international settings who are invested in the common goal of HIV cure will be key to the success of our mission. We plan to leverage recent NIH investment in the Seattle-led consortium defeatHIV, one of six Martin Delaney Collaboratories focused on the cure of HIV. We will work with UW/Fred Hutch CFAR cores and external researchers to exploit expertise across many areas, in order to develop novel research questions and subsequent grant applications for the study of curative therapies for HIV. We will also work closely with local, national, and international community members to learn what an HIV cure would mean to them, and to gain new perspectives into how an HIV cure can be realized. Collaboration is essential to our mission, and by working with people of broad experience and from diverse backgrounds we hope to serve as an internationally-recognized center for the study of curative therapies for HIV.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI027757-31
Application #
9534845
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2018-06-01
Budget End
2019-05-31
Support Year
31
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195
Merlin, Jessica S; Long, Dustin; Becker, William C et al. (2018) Brief Report: The Association of Chronic Pain and Long-Term Opioid Therapy With HIV Treatment Outcomes. J Acquir Immune Defic Syndr 79:77-82
Wagner, Anjuli D; O?Malley, Gabrielle; Firdawsi, Olivia et al. (2018) Brief Report: Disclosure, Consent, Opportunity Costs, and Inaccurate Risk Assessment Deter Pediatric HIV Testing: A Mixed-Methods Study. J Acquir Immune Defic Syndr 77:393-399
Golovaty, Ilya; Sharma, Monisha; Van Heerden, Alastair et al. (2018) Cost of Integrating Noncommunicable Disease Screening Into Home-Based HIV Testing and Counseling in South Africa. J Acquir Immune Defic Syndr 78:522-526
LaCourse, Sylvia M; Cranmer, Lisa M; Njuguna, Irene N et al. (2018) Urine Tuberculosis Lipoarabinomannan Predicts Mortality in Hospitalized Human Immunodeficiency Virus-Infected Children. Clin Infect Dis 66:1798-1801
Altekruse, Sean F; Shiels, Meredith S; Modur, Sharada P et al. (2018) Cancer burden attributable to cigarette smoking among HIV-infected people in North America. AIDS 32:513-521
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Ross, Jennifer M; Ying, Roger; Celum, Connie L et al. (2018) Modeling HIV disease progression and transmission at population-level: The potential impact of modifying disease progression in HIV treatment programs. Epidemics 23:34-41
Patel, Rena C; Bukusi, Elizabeth A; Baeten, Jared M (2018) Current and future contraceptive options for women living with HIV. Expert Opin Pharmacother 19:1-12
Stekler, Joanne D; Milne, Ross; Payant, Rachel et al. (2018) Transmission of HIV-1 drug resistance mutations within partner-pairs: A cross-sectional study of a primary HIV infection cohort. PLoS Med 15:e1002537
Wagner, Anjuli D; Shah, Seema K; Njuguna, Irene N et al. (2018) Financial Incentives to Motivate Pediatric HIV Testing-Assessing the Potential for Coercion, Inducement, and Voluntariness. J Acquir Immune Defic Syndr 78:e15-e18

Showing the most recent 10 out of 1275 publications